CJC-1295 (NO DAC) & IPAMORELIN 5MG/5MG – RESEARCH COMPOUNDS

CJC-1295 (No DAC) and Ipamorelin are synthetic peptide compounds commonly studied in laboratory research related to growth hormone regulation and endocrine signaling. CJC-1295 (No DAC) is designed to stimulate growth hormone–releasing hormone (GHRH) activity, while Ipamorelin acts as a selective growth hormone secretagogue by targeting ghrelin receptors.

Researchers examine this peptide combination to better understand pulsatile growth hormone release, metabolic signaling, and cellular recovery processes under controlled experimental conditions. Due to the absence of DAC (Drug Affinity Complex), CJC-1295 (No DAC) is studied for its shorter activity window, allowing researchers to observe more natural hormone release patterns when paired with Ipamorelin.

This compound blend is widely used in in-vitro research and early-stage laboratory studies focused on metabolism, tissue response, and endocrine pathway interactions. Scientists also explore its effects on cellular signaling mechanisms related to energy balance and protein synthesis in controlled environments.

The product is supplied in lyophilized powder form with a combined concentration of 5 mg CJC-1295 (No DAC) and 5 mg Ipamorelin. It should be stored in a cool, dry place away from light. Standard laboratory safety procedures must be followed during handling. This product is strictly intended for research and laboratory use only and is not approved for human or animal consumption, medical treatment, or cosmetic application.